Nice uote From MD Anderson President
MD Anderson President Ron DePinho, M.D., said:
Genetically engineering our patients’ immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today. We believe coupling MD Anderson’s unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson’s most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History
CyberArk Files For Secondary Offering After Strong Q1
BY GILLIAN RICH, INVESTOR'S BUSINESS DAILY
6-8-15 08:54 AM ET
CyberArk Software (NASDAQ:CYBR) said Friday it filed for a follow-on stock offering.
The cybersecurity company filed a registration statement with the Securities and Exchange Commission for the secondary offering. The majority of the shares will be sold by current shareholders with $50 million in shares to be sold by CyberArk. The total number of shares to be sold hasn't been decided yet.